Limits...
Efficacy of pamidronate in pediatric osteosarcoma patients with low bone mineral density.

Lim SW, Ahn JH, Choi A, Cho WH, Lee JA, Kim DH, Seo JH, Lim JS - Ann Pediatr Endocrinol Metab (2016)

Bottom Line: Clinical outcomes including acute side effects were also evaluated.After pamidronate treatments, all patients experienced decreased pain.The BMD of lumbar spine was increased by 0.108±0.062 mg/cm(2) after 8.4±1.0 months (n=8, P=0.017) and the mean z-score improved from -2.14±0.94 to -1.76±0.95 (P=0.161).

View Article: PubMed Central - PubMed

Affiliation: Department of Pediatrics, Korea Cancer Center Hospital, Seoul, Korea.

ABSTRACT

Purpose: Most surviving pediatric osteosarcoma patients experience osteoporosis, bone pain, and pathologic fracture during and after therapy. The aim of this study was to evaluate the efficacy and side effects of pamidronate therapy in these patients.

Methods: Nine osteosarcoma patients (12.8±1.6 years of age; 5 boys and 4 girls) who had a history of nontraumatic fracture or severe pain after completing chemotherapy were included. Intravenous pamidronate (1.5 mg/kg) was given every 6 weeks for 4 to 6 cycles. Bone mineral density (BMD) of the lumbar spine was measured by dual-energy x-ray absorptiometry. Clinical outcomes including acute side effects were also evaluated.

Results: After pamidronate treatments, all patients experienced decreased pain. Seven of 9 patients could walk without a crutch. The BMD of lumbar spine was increased by 0.108±0.062 mg/cm(2) after 8.4±1.0 months (n=8, P=0.017) and the mean z-score improved from -2.14±0.94 to -1.76±0.95 (P=0.161). Six patients (67%) had an acute-phase reaction, and 2 patients had symptomatic hypocalcemia.

Conclusion: Pamidronate appears to be safe and effective for the treatment of osteosarcoma in children with low BMD and bone pain.

No MeSH data available.


Related in: MedlinePlus

The lumbar spine bone mineral density changes after pamidronate treatment. (A) Changes in bone mineral density lumbar spine (BMDLS mg/cm2) of osteosarcoma patients (P2 to P9, case 2 to 9) at baseline and after follow-up. (B) Changes in the BMDLSz-scores of osteosarcoma patients. The interval from first BMDLS evaluation to next BMDLS evaluation was 8.4±1.0 months.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4835557&req=5

Figure 1: The lumbar spine bone mineral density changes after pamidronate treatment. (A) Changes in bone mineral density lumbar spine (BMDLS mg/cm2) of osteosarcoma patients (P2 to P9, case 2 to 9) at baseline and after follow-up. (B) Changes in the BMDLSz-scores of osteosarcoma patients. The interval from first BMDLS evaluation to next BMDLS evaluation was 8.4±1.0 months.

Mentions: The interval between BMD evaluations was 8.4±1.0 months in 8 patients (24 months in case 1). Initially, the BMDLSz-scores were –2.14±0.94 (range, –1.31 to –3.21). After treatment, the mean BMDLS increased by 0.108±0.062 mg/cm2 (P=0.017), and the mean z-score improved from –2.14±0.94 to –1.76±0.95 (P=0.161) (Fig. 1). The BMDLSz-scores of case 9 improved from and –2.42 to –0.77 by 24 months (BMDLS increased from 0.717 to 1.001 mg/cm2). Further, the BMDLSz-score of case 1 improved from –1.35 to 0.88 (BMDLS increased from 0.69 to 0.87 mg/cm2).


Efficacy of pamidronate in pediatric osteosarcoma patients with low bone mineral density.

Lim SW, Ahn JH, Choi A, Cho WH, Lee JA, Kim DH, Seo JH, Lim JS - Ann Pediatr Endocrinol Metab (2016)

The lumbar spine bone mineral density changes after pamidronate treatment. (A) Changes in bone mineral density lumbar spine (BMDLS mg/cm2) of osteosarcoma patients (P2 to P9, case 2 to 9) at baseline and after follow-up. (B) Changes in the BMDLSz-scores of osteosarcoma patients. The interval from first BMDLS evaluation to next BMDLS evaluation was 8.4±1.0 months.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4835557&req=5

Figure 1: The lumbar spine bone mineral density changes after pamidronate treatment. (A) Changes in bone mineral density lumbar spine (BMDLS mg/cm2) of osteosarcoma patients (P2 to P9, case 2 to 9) at baseline and after follow-up. (B) Changes in the BMDLSz-scores of osteosarcoma patients. The interval from first BMDLS evaluation to next BMDLS evaluation was 8.4±1.0 months.
Mentions: The interval between BMD evaluations was 8.4±1.0 months in 8 patients (24 months in case 1). Initially, the BMDLSz-scores were –2.14±0.94 (range, –1.31 to –3.21). After treatment, the mean BMDLS increased by 0.108±0.062 mg/cm2 (P=0.017), and the mean z-score improved from –2.14±0.94 to –1.76±0.95 (P=0.161) (Fig. 1). The BMDLSz-scores of case 9 improved from and –2.42 to –0.77 by 24 months (BMDLS increased from 0.717 to 1.001 mg/cm2). Further, the BMDLSz-score of case 1 improved from –1.35 to 0.88 (BMDLS increased from 0.69 to 0.87 mg/cm2).

Bottom Line: Clinical outcomes including acute side effects were also evaluated.After pamidronate treatments, all patients experienced decreased pain.The BMD of lumbar spine was increased by 0.108±0.062 mg/cm(2) after 8.4±1.0 months (n=8, P=0.017) and the mean z-score improved from -2.14±0.94 to -1.76±0.95 (P=0.161).

View Article: PubMed Central - PubMed

Affiliation: Department of Pediatrics, Korea Cancer Center Hospital, Seoul, Korea.

ABSTRACT

Purpose: Most surviving pediatric osteosarcoma patients experience osteoporosis, bone pain, and pathologic fracture during and after therapy. The aim of this study was to evaluate the efficacy and side effects of pamidronate therapy in these patients.

Methods: Nine osteosarcoma patients (12.8±1.6 years of age; 5 boys and 4 girls) who had a history of nontraumatic fracture or severe pain after completing chemotherapy were included. Intravenous pamidronate (1.5 mg/kg) was given every 6 weeks for 4 to 6 cycles. Bone mineral density (BMD) of the lumbar spine was measured by dual-energy x-ray absorptiometry. Clinical outcomes including acute side effects were also evaluated.

Results: After pamidronate treatments, all patients experienced decreased pain. Seven of 9 patients could walk without a crutch. The BMD of lumbar spine was increased by 0.108±0.062 mg/cm(2) after 8.4±1.0 months (n=8, P=0.017) and the mean z-score improved from -2.14±0.94 to -1.76±0.95 (P=0.161). Six patients (67%) had an acute-phase reaction, and 2 patients had symptomatic hypocalcemia.

Conclusion: Pamidronate appears to be safe and effective for the treatment of osteosarcoma in children with low BMD and bone pain.

No MeSH data available.


Related in: MedlinePlus